T. Jindal

发表

Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.

N. Agarwal, G. Sonpavde, A. Hsieh, 2022, Clinical genitourinary cancer.

Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series.

P. Barata, T. Friedlander, V. Koshkin, 2021, Clinical genitourinary cancer.

Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.

N. Agarwal, P. Barata, A. Cortellini, 2022, Clinical genitourinary cancer.

APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer

A. Sweet-Cordero, C. Onodera, E. Small, 2022, Frontiers in Oncology.

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

G. Sonpavde, M. Milowsky, A. Alva, 2021, Cancer.

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer

R. Bose, E. Small, S. Porten, 2023, Frontiers in Oncology.

Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma PatientsTreated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.

Julian C. Hong, M. Meng, R. Bose, 2023, Clinical genitourinary cancer.

Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.

N. Agarwal, D. Pinato, V. Koshkin, 2023, Clinical genitourinary cancer.